Immunovant Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Selling, General & Admin	76.24	77.24	57.28	48.02	54.23
Research & Development	456.66	360.92	225.43	170.26	101.81
Total Operating Expenses	532.9	438.15	282.71	218.28	156.03
Operating Income	-532.9	-438.15	-282.71	-218.28	-156.03
Interest Income	25.33	24.73	24.95	7.58	-
Other Non-Operating Income (Expense)	2.18	0.47	-1.01	-0.25	-0.78
Total Non-Operating Income (Expense)	27.51	25.2	23.94	7.33	-0.78
Pretax Income	-505.39	-412.95	-258.77	-210.95	-156.81
Provision for Income Taxes	0.22	0.89	0.57	0.01	-0.08
Net Income	-505.61	-413.84	-259.34	-210.96	-156.73
Net Income to Common	-505.61	-413.84	-259.34	-210.96	-156.73
Shares Outstanding (Basic)	182	152	138	123	110
Shares Outstanding (Diluted)	182	152	138	123	110
Shares Change (YoY)	20.35%	9.76%	12.21%	12.21%	24.98%
EPS (Basic)	-2.77	-2.73	-1.88	-1.71	-1.43
EPS (Diluted)	-2.77	-2.73	-1.88	-1.71	-1.43
Free Cash Flow	-407.32	-376.63	-214.59	-188.39	-106.37
Free Cash Flow Per Share	-2.23	-2.48	-1.55	-1.53	-0.97
EBITDA	-532.49	-437.78	-282.48	-218.08	-155.91
EBIT	-532.9	-438.15	-282.71	-218.28	-156.03
Effective Tax Rate	-0.04%	-0.22%	-0.22%	-0.00%	0.05%

SEC Filings: 10-K · 10-Q